ANGPTL1 is a potential biomarker for differentiated thyroid cancer diagnosis and recurrence

Sun,Rongxin; Yang,Longyan; Hu,Yangping; Wang,Yan; Zhang,Qiang; Zhang,Yuanyuan; Ji,Zhili; Zhao,Dong

doi:10.3892/ol.2020.12103

ANGPTL1 is a potential biomarker for differentiated thyroid cancer diagnosis and recurrence

Authors:
- Rongxin Sun
- Longyan Yang
- Yangping Hu
- Yan Wang
- Qiang Zhang
- Yuanyuan Zhang
- Zhili Ji
- Dong Zhao
View Affiliations

Affiliations: Beijing Key Laboratory of Diabetes Prevention and Research, Department of Endocrinology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, P.R. China, Department of Pathology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, P.R. China, Department of General Surgery, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, P.R. China
Published online on: September 15, 2020 https://doi.org/10.3892/ol.2020.12103
Article Number: 240
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Differentiated thyroid cancer (DTC) is a common type of cancer among women with an increasing worldwide incidence rate. However, there are no specific and sensitive molecular biomarkers for DTC diagnosis or prognosis. Angiopoietin‑like protein 1 (ANGPTL1) may be a novel tumor suppressor in lung, breast, colorectal and hepatocellular carcinoma. However, little is known about the influence of ANGPTL1 on the malignant properties of thyroid cancer cells or DTC recurrence in patients. Thus, the present study aimed to investigate the effects of ANGPTL1 on thyroid cancer malignancy or recurrence. The present study examined the mRNA levels of ANGPTL1 in thyroid cancer and paracancerous tissues using RNA sequencing data from The Cancer Genome Atlas. The present study also determined the effects of ANGPTL1 on thyroid cancer cell proliferation using the Cell Counting Kit‑8 assay. Associations were identified among ANGPTL1 expression levels and thyroid cancer proliferation, migration and metastasis using The Cancer Genome Atlas data set and by Gene Set Enrichment Analysis. The expression of ANGPTL1 in patients with DTC and without recurrence was compared in order to assess its potential as a prognostic biomarker for DTC. In addition, ANGPTL1 concentrations in the serum of patients with DTC and individuals with benign thyroid nodules were compared to evaluate the sensitivity and specificity of ANGPTL1 as a predictive biomarker for DTC. The results of the present study demonstrated that ANGPTL1 expression levels were lower in thyroid cancer compared with those in adjacent normal thyroid tissues. ANGPTL1 expression was observed to decrease with thyroid cancer progression. In addition, ANGPTL1 was demonstrated to inhibit thyroid cancer cell proliferation, migration and invasion and ANGPTL1 expression levels were reduced in patients with DTC with recurrence compared with those in patients with non‑recurrent DTC. Additionally, serum concentrations of ANGPTL1 in patients with DTC were decreased compared with those in individuals with benign thyroid nodules. In conclusion, ANGPTL1 may be a novel predictive biomarker for DTC diagnosis and recurrence in patients with DTC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Viola D, Valerio L, Molinaro E, Agate L, Bottici V, Biagini A, Lorusso L, Cappagli V, Pieruzzi L, Giani C, et al: Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience. Endocr Relat Cancer. 23:R185–R205. 2016. View Article : Google Scholar : PubMed/NCBI
3	Patel UJ and May M: Lenvatinib in the treatment of differentiated thyroid cancer and advanced renal cell carcinoma. J Adv Pract Oncol. 8:757–64. 2017.PubMed/NCBI
4	Oyer SL, Fritsch VA and Lentsch EJ: Comparison of survival rates between papillary and follicular thyroid carcinomas among 36,725 patients. Ann Otol Rhinol Laryngol. 123:94–100. 2014. View Article : Google Scholar : PubMed/NCBI
5	Toniato A, Boschin I, Casara D, Mazzarotto R, Rubello D and Pelizzo M: Papillary thyroid carcinoma: Factors influencing recurrence and survival. Ann Surg Oncol. 15:1518–1522. 2008. View Article : Google Scholar : PubMed/NCBI
6	Carbone C, Piro G, Merz V, Simionato F, Santoro R, Zecchetto C, Tortora G and Melisi D: Angiopoietin-like proteins in angiogenesis, inflammation and cancer. Int J Mol Sci. 19:4312018. View Article : Google Scholar
7	Cinkajzlová A, Mráz M, Lacinová Z, Kloučková J, Kaválková P, Kratochvílová H, Trachta P, Křížová J, Haluzíková D, Škrha J, et al: Angiopoietin-like protein 3 and 4 in obesity, type 2 diabetes mellitus, and malnutrition: The effect of weight reduction and realimentation. Nutr Diabetes. 8:212018. View Article : Google Scholar : PubMed/NCBI
8	Geladari E, Tsamadia P and Vallianou NG: ANGPTL3 inhibitors-their role in cardiovascular disease through regulation of lipid metabolism. Circ J. 83:267–273. 2019. View Article : Google Scholar : PubMed/NCBI
9	Hato T, Tabata M and Oike Y: The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc Med. 18:6–14. 2008. View Article : Google Scholar : PubMed/NCBI
10	Zhang CC, Kaba M, Ge G, Xie K, Tong W, Hug C and Lodish HF: Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells. Nat Med. 12:240–245. 2006. View Article : Google Scholar : PubMed/NCBI
11	Zhu P, Tan MJ, Huang RL, Tan CK, Chong HC, Pal M, Lam CR, Boukamp P, Pan JY, Tan SH, et al: Angiopoietin-like 4 protein elevates the prosurvival intracellular O₂(−):H₂O₂ ratio and confers anoikis resistance to tumors. Cancer Cell. 19:401–415. 2011. View Article : Google Scholar : PubMed/NCBI
12	Tabata M, Kadomatsu T, Fukuhara S, Miyata K, Ito Y, Endo M, Urano T, Zhu HJ, Tsukano H, Tazume H, et al: Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. Cell Metab. 10:178–188. 2009. View Article : Google Scholar : PubMed/NCBI
13	Kim I, Kwak HJ, Ahn JE, So JN, Liu M, Koh KN and Koh GY: Molecular cloning and characterization of a novel angiopoietin family protein, angiopoietin-3. FEBS Lett. 443:353–356. 1999. View Article : Google Scholar : PubMed/NCBI
14	Dhanabal M, Jeffers M, LaRochelle WJ and Lichenstein HS: Angioarrestin: A unique angiopoietin-related protein with anti-angiogenic properties. Biochem Biophys Res Commun. 333:308–315. 2005. View Article : Google Scholar : PubMed/NCBI
15	Dhanabal M, LaRochelle WJ, Jeffers M, Herrmann J, Rastelli L, McDonald WF, Chillakuru RA, Yang M, Boldog FL, Padigaru M, et al: Angioarrestin: An antiangiogenic protein with tumor-inhibiting properties. Cancer Res. 62:3834–3841. 2002.PubMed/NCBI
16	Smagur A, Szary J and Szala S: Recombinant angioarrestin secreted from mouse melanoma cells inhibits growth of primary tumours. Acta Biochim Pol. 52:875–879. 2005. View Article : Google Scholar : PubMed/NCBI
17	Kuo TC, Tan CT, Chang YW, Hong CC, Lee WJ, Chen MW, Jeng YM, Chiou J, Yu P, Chen PS, et al: Angiopoietin-like protein 1 suppresses SLUG to inhibit cancer cell motility. J Clin Invest. 127:4202017. View Article : Google Scholar
18	Sasaki H, Moriyama S, Sekimura A, Mizuno K, Yukiue H, Konishi A, Yano M, Kaji M, Fukai I, Yamakawa Y and Fujii Y: Angioarrestin mRNA expression in early-stage lung cancers. Eur J Surg Oncol. 29:649–653. 2003. View Article : Google Scholar : PubMed/NCBI
19	Chen H, Xiao Q, Hu Y, Chen L, Jiang K, Tang Y, Tan Y, Hu W, Wang Z, He J, et al: ANGPTL1 attenuates colorectal cancer metastasis by up-regulating microRNA-138. J Exp Clin Cancer Res. 36:782017. View Article : Google Scholar : PubMed/NCBI
20	Yan Q, Jiang L, Liu M, Yu D, Zhang Y, Li Y, Fang S, Li Y, Zhu YH, Yuan YF and Guan XY: ANGPTL1 Interacts with Integrin alpha1beta1 to Suppress HCC Angiogenesis and Metastasis by Inhibiting JAK2/STAT3 Signaling. Cancer Res. 77:5831–5845. 2017. View Article : Google Scholar : PubMed/NCBI
21	Zhang C, Bo C, Guo L, Yu P, Miao S and Gu X: BCL2 and hsa-miR-181a-5p are potential biomarkers associated with papillary thyroid cancer based on bioinformatics analysis. World J Surg Oncol. 17:2212019. View Article : Google Scholar : PubMed/NCBI
22	Liu Y, Gao S, Jin Y, Yang Y, Tai J, Wang S, ang H, Chu P, Han S and Lu J: Bioinformatics analysis to screen key genes in papillary thyroid carcinoma. Oncol Lett. 19:195–204. 2020.PubMed/NCBI
23	Tuttle RM, Haugen B and Perrier ND: Updated American Joint Committee on Cancer/Tumor-Node-Metastasis staging system for differentiated and anaplastic thyroid cancer (Eighth Edition): What changed and Why? Thyroid. 27:751–756. 2017. View Article : Google Scholar : PubMed/NCBI
24	Adam MA, Thomas S, Roman SA, Hyslop T and Sosa JA: Rethinking the Current American Joint Committee on Cancer TNM staging system for medullary thyroid cancer. JAMA Surg. 152:869–876. 2017. View Article : Google Scholar : PubMed/NCBI
25	Chang Z, Cai C, Han D, Gao Y, Li Q, Feng L, Zhang W, Zheng J, Jin J, Zhang H and Wei Q: Anoctamin5 regulates cell migration and invasion in thyroid cancer. Int J Oncol. 51:1311–1319. 2017. View Article : Google Scholar : PubMed/NCBI
26	Shang H, Wang S, Yao J, Guo C, Dong J and Liao L: Salidroside inhibits migration and invasion of poorly differentiated thyroid cancer cells. Thorac Cancer. 10:1469–1478. 2019. View Article : Google Scholar : PubMed/NCBI
27	Chen DL, Hu ZQ, Zheng XF, Wang XY, Xu YZ, Li WQ, Fang HS, Kan L and Wang SY: EDAG-1 promotes proliferation and invasion of human thyroid cancer cells by activating MAPK/Erk and AKT signal pathways. Cancer Biol Ther. 17:414–421. 2016. View Article : Google Scholar : PubMed/NCBI
28	Yarchoan M, Ma C, Troxel AB, Stopenski SJ, Tang W, Cohen AB, Pappas-Paxinos M, Johnson BA III, Chen EY, Feldman MD and Brose MS: pAKT expression and response to sorafenib in differentiated thyroid cancer. Horm Cancer. 7:188–195. 2016. View Article : Google Scholar : PubMed/NCBI
29	Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F and Schlumberger M: Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 91:2892–2899. 2006. View Article : Google Scholar : PubMed/NCBI
30	Liu J, Liu Y, Lin Y and Liang J: Radioactive Iodine-refractory differentiated thyroid cancer and redifferentiation therapy. Endocrinol Metab (Seoul). 34:215–225. 2019. View Article : Google Scholar : PubMed/NCBI
31	Zhang RH, Wang S, Zhang H, Lan JJ, Xu GB, Zhao YL, Wang L, Li YJ, Wang YL, Zhou YH, et al: Discovery of tetrandrine derivatives as tumor migration, invasion and angiogenesis inhibitors. Bioorg Chem. 101:1040252020. View Article : Google Scholar : PubMed/NCBI
32	Chen HA, Kuo TC, Tseng CF, Ma JT, Yang ST, Yen CJ, Yang CY, Sung SY and Su JL: Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma. Hepatology. 64:1637–1651. 2016. View Article : Google Scholar : PubMed/NCBI